WALTHAM, Mass.--(BUSINESS WIRE)--March 23, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to treat cancer and certain ophthalmologic diseases, today announced that the Company has successfully completed patient enrollment in a Phase II clinical trial for the treatment of imageable solid tumors. The trial, which is being conducted in the United States under OXiGENE's Investigational New Drug (IND) application on file with the Food and Drug Administration, is designed to evaluate the safety and anti-cancer activity of the triple combination of Combretastatin A4P (CA4P)--OXiGENE's lead therapeutic candidate--together with widely-used chemotherapy agents, carboplatin and paclitaxel. OXiGENE expects the presentation of top line data later in 2006, as patients enrolled in this trial are continuing to receive prolonged therapy.
